ArticleGenome medicine2016
Lower IgG somatic hypermutation rates during acute dengue virus infection is compatible with a germinal center-independent B cell response.
Article in Genome medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 49 citations in OpenAlex.
- Potent Plasmablast-Derived Antibodies Elicited by the National Institutes of Health Dengue Vaccine.Journal of virology · 2017Trial
- Potent Cross-Serotype Dengue Neutralization with Low ADE by AG-Strand-Targeting Anti-EDIII Antibodies.ACS omega · 2026Article
- Pathogenesis and host response to a novel Tacaribe virus isolate in experimentally-infected Jamaican fruit bats.bioRxiv : the preprint server for biology · 2026Article
- Factors determining the outcomes of immune imprinting after repeated orthoflavivirus infections.Frontiers in immunology · 2025Review
- Alterations in BCR heavy chain CDR3 repertoire characteristics in pediatric mycoplasma pneumoniae infection.Frontiers in cellular and infection microbiology · 2025Article
- Article
- The dengue-specific immune response and antibody identification with machine learning.NPJ vaccines · 2024Article
- BCR, not TCR, repertoire diversity is associated with favorable COVID-19 prognosis.Frontiers in immunology · 2024Article
- Characterization of B-cell receptor clonality and immunoglobulin gene usage at multiple time points during active SARS-CoV-2 infection.Journal of medical virology · 2023Article
- Dengue virus neutralizing antibody: a review of targets, cross-reactivity, and antibody-dependent enhancement.Frontiers in immunology · 2023Review
- Structural and immunological basis of cross-reactivity between dengue and Zika infections: Implications in serosurveillance in endemic regions.Frontiers in microbiology · 2023Review
- Article
- Dengue Infection - Recent Advances in Disease Pathogenesis in the Era of COVID-19.Frontiers in immunology · 2022Review
- Article
- Integrated single-cell analysis revealed immune dynamics during Ad5-nCoV immunization.Cell discovery · 2021Article
- Prospective Artificial Intelligence to Dissect the Dengue Immune Response and Discover Therapeutics.Frontiers in immunology · 2021Review
- Robust Plasma Cell Response to Skin-Inoculated Dengue Virus in Mice.Journal of immunology research · 2021Article
- Lower Somatic Mutation Levels in theEvidence-based complementary and alternative medicine : eCAM · 2021Article
- Machine Learning Detects Anti-DENV Signatures in Antibody Repertoire Sequences.Frontiers in artificial intelligence · 2021Article
- Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe study of human B cell response to dengue virus (DENV) infection is critical to understand serotype-specific protection and the cross-reactive sub-neutralizing response. Whereas the first is beneficial and thus represents the ultimate goal of vaccination, the latter has been implicated in the development of severe disease, which occurs in a small, albeit significant, fraction of secondary DENV infections. Both primary and secondary infections are associated with the production of poly-reactive and cross-reactive IgG antibodies.
methodsTo gain insight into the effect of DENV infection on the B cell repertoire, we used VH region high-throughput cDNA sequencing of the peripheral blood IgG B cell compartment of 19 individuals during the acute phase of infection. For 11 individuals, a second sample obtained 6 months later was analyzed for comparison. Probabilities of sequencing antibody secreting cells or memory B cells were estimated using second-order Monte Carlo simulation.
resultsWe found that in acute disease there is an increase in IgG B cell diversity and changes in the relative use of segments IGHV1-2, IGHV1-18, and IGHV1-69. Somewhat unexpectedly, an overall low proportion of somatic hypermutated antibody genes was observed during the acute phase plasmablasts, particularly in secondary infections and those cases with more severe disease.
conclusionsOur data are consistent with an innate-like antiviral recognition system mediated by B cells using defined germ-line coded B cell receptors, which could provide a rapid germinal center-independent antibody response during the early phase of infection. A model describing concurrent T-dependent and T-independent B cell responses in the context of DENV infection is proposed, which incorporates the selection of B cells using hypomutated IGHV segments and their potential role in poly/cross-reactivity. Its formal demonstration could lead to a definition of its potential implication in antibody-dependent enhancement, and may contribute to rational vaccine development efforts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.